Status:
COMPLETED
Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
Lead Sponsor:
Perrigo Company
Conditions:
Bioavailability
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.
Eligibility Criteria
Inclusion
- healthy men or women 18 years of age or older
- body mass index below 30.0 kg/m2
- willing to participate and sin a copy of the informed consent form
Exclusion
- recent history of drug or alcohol addiction or abuse
- pregnant or lactating women
- history of allergic response to heparin, famotidine, other H2-receptor antagonists, or other related drugs
- evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
- recipient of any drugs as part of a research study within 30 days prior to study dosing
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00802828
Start Date
June 1 2004
Last Update
March 16 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.